Skip to main content
. 2014 Jan 31;9(1):e83786. doi: 10.1371/journal.pone.0083786

Table 1. Patient characteristics.

No. Cohort Age (years) Gender Disease ECOG/PS Prior treatment Combined treatment (chemotherapy)
1 Cohort 1 52 M colonic cancer 0 1st line, mFOLFOX62nd line, S-1 S-1
2 Cohort 1 62 M pancreatic cancer 1 1st line, GEM2nd line, S-1 S-1
3 Cohort 1 60 M gastric cancer 0 1st line, S-1 S-1
4 Cohort 2 72 F rectal cancer 0 1st line, mFOLFOX62nd line, Capectabine S-1
5 Cohort 2 61 F bile duct cancer 1 1st line, GEM2nd line, S-1 S-1
6 Cohort 2 75 M lung cancer 1 1st line, GEM/CDDP2nd line, DTX none
7 Cohort 3 48 M hepatocellular carcinoma 1 1st line, 5-FU/CDDP none
8 Cohort 3 43 M bile duct cancer 1 1st line, GEM2nd line, GEM/S-1 S-1
9 Cohort 3 53 M rectal cancer 1 1st line, mFOLFOX6+bevacizumab2nd line, FOLFIRI 3rd line, CPT-11+cetuximab S-1

ECOG = Eastern Cooperative Oncology Group.

PS = performance status.